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1607-551X/Copyright ª 2015, KaohsiuAbstract Gastrointestinal (GI) endoscopy is the major technique for diagnosis of GI disease
and treatment. Various sedation and analgesia regimens such as midazolam, fentanyl, and pro-
pofol can be used during GI endoscopy. The purpose of the study was to compare propofol
alone and propofol combination with midazolam and fentanyl in moderate sedation for GI
endoscopy. One hundred patients undergoing GI endoscopy were enrolled in this study. All pa-
tients received a propofol target-controlled infusion (TCI) to maintain sedation during the pro-
cedure. Patients were randomly allocated into either Group P (propofol TCI alone) or Group C
(combination of propofol TCI plus midazolam and fentanyl). Dermographic data, anesthetic pa-
rameters (sedation regimen, blood pressure, heart rate, and oxygen saturation), procedure pa-
rameters (procedure time, colonoscopy, or panendoscopy), propofol consumption, and
adverse events (hypoxia, hypotension, and bradycardia) were all recorded. Postprocedural re-
cords included recovery time, postoperative adverse events (nausea, vomiting, dizziness,
recall, and pain) and satisfaction. The average propofol consumption was 251  83 mg in Group
P and 159  73 mg in Group C (p < 0.001). The incidence of transient hypotension was higher in
Group P (p Z 0.009). The recovery time and discharge time were both shorter in Group Ceclare no conflicts of interests.
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Propofol TCI for GI endoscopy 581(p < 0.001 and pZ 0.006 respectively). Overall, postprocedural adverse events were similar in
both groups. The postanesthetic satisfaction was comparable in both groups. TCI of propofol
combined with midazolam and fentanyl achieved sedation with fewer hypotension episodes
and shorter recovery and discharge time than propofol TCI alone in patients undergoing GI
endoscopy.
Copyright ª 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Gastrointestinal (GI) endoscopy is considered the major
technique for diagnosis of GI disease and treatment.
Various sedation and analgesia regimens primarily intend to
diminish anxiety, discomfort, and achieve better tolera-
bility and satisfaction. In many developed countries, most
patients undergo GI endoscopy under sedation and anal-
gesia [1e3]. Sedation for the GI endoscopic examination
has also become more popular in Taiwan.
Various sedation and analgesia techniques have been
proposed for sedated GI endoscopy. The currently used
regimens include propofol, benzodiazepines (such as mid-
azolam and diazepam), opioids (such as fentanyl and
remifentanil), ketamine, and de-dexmedetomidine [3e6].
Among them propofol has become popular in developed
countries, because it provides rapid onset and safe and
effective sedation, and is associated with rapid recovery
profile [5,7]. However, propofol sedation is associated with
dose-related side effects including airway obstruction and
respiratory and cardiovascular suppression [8e10].
Target-controlled infusion (TCI) achieves the desired
concentration of drugs in plasma or the effect site by an
automatic administration system based on a pharmacoki-
netic model-based computer calculation [11,12]. The TCI
system requires several demographic parameters such as
age, sex, body weight, and height to determine the rate of
infusion. Theoretically, TCI provides a more precise control
of propofol concentration than the intermittent bolus
methods, which result in many peaks and troughs of pro-
pofol level. Only limited reports have investigated propofol
TCI in sedated GI endoscopy [13e15]; instead, propofol was
administrated by intermittent bolus methods in most non-
anesthesiologist practices [16,17].
Sedation and analgesia may be accompanied by cardio-
vascular and respiratory suppression; hence, the primary
goals of sedation for GI endoscopy are patient safety and
comfort. We hypothesized that a combined regimen might
reduce propofol dosage resulting in less hypotension epi-
sodes and faster recovery. The aim of this observational
study was to compare the safety (adverse events) and ef-
ficacy (satisfaction and recovery) of the synergistic effect
of propofol TCI combined with midazolam and fentanyl
versus propofol TCI alone titrated to sedation during diag-
nostic GI endoscopy in a Taiwanese population.Methods
The study was approved by the Institutional Review Board
(Kaohsiung Medical University Hospital, Kaohsiung City,
Taiwan) and informed consent was obtained from each
patient. One hundred patients with GI problems who were
undergoing a diagnostic colonoscopy and/or upper GI
endoscopy were enrolled in this study. Exclusion criteria
were: patient refusal to participate or inability to provide
informed consent; age under 18 years; pregnant and
lactating women; American Society of Anesthesiologists
(ASA) class IV; allergy to propofol, fentanyl, or benzodiaz-
epine; and anticipated difficult airway.
Physical monitoring included electrocardiography (lead
II), heart rate, peripheral oxygen saturation, capnography,
and noninvasive blood pressure (every 5 minutes). Abdom-
inal wall and chest excursions were also monitored using
inspection and palpation. Baseline vital signs were recor-
ded for all patients before sedation. All patients received
oxygen 2 L/min via nasal cannula throughout the proce-
dure. Before the systemic administration of intravenous
(IV) anesthetics, IV scopolamine 20 mg was given to
decrease bowel movement. All patients received a propofol
TCI by the Base Primea system (Fresenius, Brezins, France)
as the mainstay of sedation regimen.
The nurse anesthetists administered the IV anesthetics
under the supervision of anesthesiologists and were certi-
fied in advanced cardiac life support. Patients were allo-
cated into propofol alone (Group P) or combination regimen
(Group C) according to anesthetics use. For Group P pri-
marily receiving propofol TCI alone, low dose of fentanyl
bolus (25e50 mg) could be added as a rescue during
endoscopy. Group C received IV midazolam (1e2 mg) and
fentanyl (25e50 mg) routinely before propofol TCI. Ac-
cording to our previous report [13], the initial effect site
concentration (Ce) of propofol TCI system was set at
4.0e5.0 mg/mL for upper GI endoscopy, while the initial Ce
of propofol TCI system was 2.0e3.0 mg/mL for colonos-
copy. Ce of propofol TCI was further titrated using 0.5 mg/
mL step-size patient response. Patient response was eval-
uated by the modified observer’s assessment of alertness/
sedation (MOAA/S) [2,13].The procedure began when the
patient did not respond to eyelid stimulation (MOAA/S
scores of 2). If patient movement occurred and might
interfere with endoscopic examination, a bolus of fentanyl
582 C.-D. Hsu et al.(25e50 mg) was used as a rescue therapy in each group.
When patients responded to stimulus call after the endos-
copy examination, they were transferred to the recovery
room. The outcomes recording and postanesthesia inter-
view were performed by another observer who was blinded
to the regimen.
The procedure time was defined as the time of the first
endoscope insertion until the last endoscope removal. Re-
covery time was defined as the time from endoscope
withdrawal to when an MOAA/S score of 5 was achieved.
The Aldrete scoring system was used as the discharge
criteria from recovery area. The patient was discharged
after full recovery. Discharge time was defined as the time
of arrival at the recovery room. Propofol dosage and hy-
potension episodes were considered as primary outcomes.
Anesthetic records included demographic data, ASA
class, endoscopic procedure, sedation regimen (each drug
dosage), and procedure time. Patient safety evaluation
included all adverse events during procedure. Transient
hypoxia was defined as peripheral oxygen saturation
<90% < 60 seconds. Required airway management such as
jaw lifting, mask ventilation, or tracheal intubation was
also recorded. Hypotension episode was defined as systolic
blood pressure <90 mmHg. Bradycardia was defined as a
heart rate <50 beats/min. Involuntary movement was
defined as unconscious movement requirement restraint or
severe limb movement interrupting the endoscopy
procedure.
The efficacy was measured by satisfaction and recovery
profile from sedation. Satisfaction evaluation involved both
endoscopists and patients. Endoscopy overall satisfaction
was assessed subjectively by patient safety, patient coop-
eration and fluency of the procedure. Telephone interviews
of patients were performed the next day to ascertain the
overall satisfaction. The satisfaction was scored by a 4-
scale questionnaire as: excellent, good, fair, and poor.
Postprocedural records included recovery time, discharge
time, and postprocedural adverse events (nausea, vomit-
ing, dizziness, recall, and pain).
All data were presented as mean  standard deviation. A
power analysis identified a minimal sample size of 25 pa-
tients per group to demonstrate a 30% difference in pro-
pofol dosage with a power of 0.9 and a type-1 error of 0.05.
Therefore, we recruited 50 patients in each group to allowTable 1 Patient characteristics between groups.
Group P (
Sex (male:female) 23:27
Age (y) 56.6 
Weight (kg) 59.9 
Height (cm) 161.3 
ASA I/II/III (n) 11/35/4
Colonoscopy/and upper GI endoscopy (n) 35/15
Procedure time (min) 26.9 
Propofol dose (mg) 251.8 
Fentanyl dose (mg) 12.5 
Midazolam dose (mg) 0
ASA Z American Society of Anesthesiologists; GI Z gastrointestinal;for study error and attrition. Statistical analysis was carried
out using two-sample t tests (numerical variables) and Chi-
square tests (categorical variables). Fisher’s exact test was
used for noncontinuous data with non-normal distribution.
The SPSS version 14.0 statistical software package (SPSS
Inc., Chicago, IL, USA) was used for all analyses and p
values < 0.05 were considered statistically significant.Results
Patient characteristics of the patients are shown in Table 1.
The demographic data, ASA class, received procedure, and
procedure time did not differ significantly between groups.
The average propofol consumption was significantly higher
in Group P than in Group C (251  83 mg vs 159  73 mg; p <
0.001). Both fentanyl and midazolam dosage were obviously
higher in Group C than in Group P (Table 1). All colonos-
copies and upper GI endoscopies were completed success-
fully. No procedure was terminated due to inadequate
sedation or anesthetic adverse events.
Patient safety profiles during procedure are shown in
Table 2. There was no severe complication such as persis-
tent hypoxia or tracheal intubation during the study.
Transient hypoxia were noted in 16% (8/50) and 6% (3/50) in
Group P and Group C, respectively (p Z 0.11). All patients
regained normal saturation with jaw lifting. None of them
required mask ventilation or interruption of the procedure.
With respect to cardiovascular events, patients in Group C
depicted significantly fewer hypotension episodes than did
Group P (8% vs 28%, p Z 0.009). The incidence of brady-
cardia was similar between groups (Table 2). All hypoten-
sion and bradycardia events were transient and patients
recovered after the titration dose of propofol. Adminis-
tration of inotropic or vasopressor was not required. Only a
few patients moved involuntarily during the procedure in
either group (Table 2). The overall satisfaction of the
endoscopists was similar in both groups.
Table 3 reveals recovery profile and patient satisfaction.
Both recovery time and discharge time were shorter in
Group C (p < 0.001 and p Z 0.006 respectively). Overall,
postprocedural adverse events were similar in both groups.
The postanesthetic satisfaction was comparable in both
groups.n Z 50) Group C (n Z 50) p
18:32 0.31
12.5 55.4  13.6 0.64
10.3 61.3  10.2 0.51
7.6 161.8  8.7 0.76
8/36/6 0.64
31/19 0.39
8.7 25.1  10.9 0.32
83.1 159.1  73.3 <0.001
25.3 52.5  9.1 <0.001
1.1  0.3 NA
NA Z not available.






Transient hypoxia 8 (16) 3 (6) 0.11
Hypotension 14 (28) 4 (8) 0.009
Bradycardia 2 (4) 3 (6) 0.65











Recovery time (min) 9.4  5.4 2.4  2.6 <0.001
Discharge time (min) 41.9  13.5 34.1  15.4 0.006
Adverse events
Nausea/vomiting 0 (0) 0 (0) > 0.99
Dizziness 5 (10) 1 (2) 0.09
Recall 0 (0) 1 (2) 0.32
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This study demonstrates that the patients who received
midazolamefentanylepropofol TCI had fewer propofol
consumption incidences than those receiving propofol TCI
alone. The reduction in propofol dosage was followed by
less hypotension episode and shorter recovery and
discharge periods. We found no significant difference with
respect to postanesthetic satisfaction and postprocedural
adverse events.
The cardinal goals of sedation in GI endoscopy are rapid
onset of hypnosis, anxiolysis, analgesia, amnesia, cooper-
ation to complete the procedure, and rapid recovery of
consciousness [7,13]. Propofol is an ultrashort-acting IV
anesthetic with a rapid off set property. Its pharmacolog-
ical effects make it an ideal sedative agent for GI endos-
copy. The safety and effectiveness of propofol sedation in
GI endoscopy has been demonstrated when compared to
traditional agents such as benzodiazepines and opioids
[2,18,19]. Wang et al [7] revealed that propofol provided
excellent sedation for patients undergoing GI endoscopy
procedures. Propofol sedation also shortened recovery and
discharge periods, improved greater patient cooperation
when compared to traditional sedation, and is not associ-
ated with increased cardiopulmonary complications.
Various techniques can be used in propofol administra-
tion including intermittent bolus method, continuous infu-
sion method, patient-controlled sedation and TCI method
[5,20]. However, only a few reports have describedpropofol TCI technique in sedation for GI endoscopy. Hsu
et al [13] and Pao et al [15] described propofol TCI during
colonoscopy and/or upper GI endoscopy in a Taiwanese
population. The former also revealed that propofol at low
Ce (1.5e2.5 mg/mL) is effective and has fewer cardiovas-
cular events [15]. Another report revealed that propofol TCI
provided excellent sedation and reduced severe cardio-
vascular and respiratory depression than did intermittent
bolus propofol with midazolam/alfentanil regimen [14].
Propofol can be given alone or in combination with an
opioid or a benzodiazepine. This study revealed that pro-
pofol TCI combined with midazolam/fentanyl versus pro-
pofol TCI alone reduced propofol dosage, produced less
hypotension and shortened recovery time and discharge
time. When propofol was administrated with intermittent
bolus method, many reports showed that propofol com-
bined with traditional sedation agents during GI endoscopy
could significantly reduce the total dose of propofol
compared with propofol-alone sedation [17,21e23]. Hsieh
et al [23] compared intermittent bolus propofol alone and
propofol in combination with meperidine and found that
the combination regimen is better in improving tolerance
and recovery for sedated colonoscopy. Furthermore,
intermittent bolus propofol in combination with fentanyl
and/or midazolam achieved shorter recovery period versus
propofol alone for colonoscopy [22]. Recently, Chan et al
evaluated propofol TCI alone versus intermittent bolus of
propofol with midazolam/alfentanil regimen and demon-
strated that propofol TCI alone produced less hypoxia and
bradycardia with comparable satisfaction [14]. Therefore,
propofol TCI either alone or in combination with traditional
agents might be a better option than the intermittent bolus
method.
There were several limitations in this study. First, the
depth of anesthesia would be more precise when it was
monitored by entrophy or bispectral index. Since both
monitors were not available in the endoscopy room, depth
of anesthesia could be only assessed by clinical observation
by experienced personnel. Second, the study population
was limited to those undergoing colonoscopy with or
without upper GI endoscopy; therefore, the efficacy of
propofol TCI was undetermined in patients merely under-
going upper GI endoscopy. Third, there were three major
experienced endoscopists involved in this study. The indi-
vidual technique difference between endoscopists was
difficult to evaluate because of limited sample size. Finally,
several factors such as alcohol drinking or betel nut chew-
ing may be crucial in determination of propofol dosage. In
the study design, we focused on the differences between
regimens and did not study those factors, which deserve
further investigation.
In conclusion, this study demonstrated that propofol TCI
by anesthesiologists provided safe and effective sedation in
patients undergoing diagnostic GI endoscopy. Propofol TCI
in combination with low dose midazolam and fentanyl
achieved sedation with less hypotension episode and
shorter recovery and discharge period compared to propo-
fol TCI alone. Although our data suggest that propofol TCI
combination therapy could be successfully used by anes-
thesiologists, the benefit of propofol combination regimen
remains to be determined when it is used by
nonanesthesiologists.
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